--- title: 'Vice President, Nonclinical Drug Safety & Toxicology at Remix Therapeutics' canonical: 'https://feeny.ai/job/vice-president-nonclinical-drug-safety-toxicology-remix-therapeutics-watertown-hcv58wta0q0b' type: 'job' last_seen: '2026-09-12' --- # Vice President, Nonclinical Drug Safety & Toxicology at Remix Therapeutics - **Company:** Remix Therapeutics - **Location:** Watertown, MA - **Posted:** 2026-09-09 - **Last confirmed live:** 2026-09-12 - **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4732444005 ## Job description Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors. Position Summary: Reporting to the Chief Scientific Officer, the Vice President of Nonclinical Drug Safety and Toxicology is a key position within the R&D leadership team and will lead nonclinical aspects of all the company’s pipeline programs. As the most senior toxicology expert within the organization, the VP will be responsible for providing strategic and operational leadership for the toxicology group across the portfolio of discovery, early development, and late development programs. The Non-Clinical Safety and Toxicology leader will partner cross-functionally across therapeutic areas with colleagues in drug discovery, translational, and clinical development functions, ensuring toxicology and nonclinical safety data is shared and communicated transparently and plays a role in informing strategy at all stages of each program’s development. Key Responsibilities: Areas of specific responsibility and attention will include the following: - Create a long-term global toxicology strategy in alignment with the company’s vision and objectives, including multi-year scientific and operational plans - Lead scientific direction for global regulatory toxicology including safety pharmacology - Lead scientific direction for safety assessments of discovery and early development programs, aligning with program objectives and regulatory strategies - Oversee toxicology findings and provide advice to project teams and senior management on potential impact of results on program goals and probability of success - Collaboratively design and implement external toxicity studies (in vitro and in vivo) required for lead optimization, and development candidate selection - Develop strategy, plan and budget to effectively manage regulatory toxicity studies (in vitro and in vivo) required for IND and NDA submissions, including general toxicity, juvenile toxicity, genotoxicity, safety pharmacology, reproductive and developmental, and carcinogenicity studies - Work with internal R&D leaders and external parties including development partners, consultants, CROs and approved vendors based on a balance of quality, timeliness, and cost - Develop and manage all timelines related to this function - Identify and engage experts in the field of toxicology (e.g., consultants) to interpret study results and make recommendations, as needed - Communicate toxicity study results to discovery program and development teams, and to the company’s executive management and Board of Directors, as needed - Actively participate in regulatory meetings - Other duties as assigned Qualifications: - PhD in toxicology or related discipline with at least 15 years of experience, (an equivalent combination of experience and education may be considered) - Preferred 10 years of experience managing and developing a drug safety/toxicology team - DABT certification strongly preferred - Experience in defining and implementing scientifically relevant and compliant nonclinical toxicology strategies and contingency plans addressing both theoretical and identified nonclinical safety issues - Collaborative mindset capable of excelling within multi-discipline discovery and development teams - Proven track record of interfacing with global regulatory authorities, and the design and interpretation of safety studies for regulatory submissions, including INDs and NDAs - Deep knowledge of FDA and EMA requirements and guidance for nonclinical safety submissions - Strong communication (written and oral) and interpersonal skills with an ability to effectively function within a matrixed environment Salary Range $293,000 - $358,000 USD This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role. ## About Remix Therapeutics ## Company Overview - **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases. - **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement) - **Headquarters**: Watertown, Massachusetts, United States - **Founded**: 2018 - **Founders**: Peter Smith, PhD ## Core Business - **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology - **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers) - **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin ## Products & Services - **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC. - **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs. ## Market Standing - **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown) - **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech). - **Notable Investors/Partners**: - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M) - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration) - **Growth Signals**: - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC - FDA Fast Track designation for REM‑422 in ACC - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies - Active job postings up 200% month‑over‑month and quarter‑over‑quarter - Headcount of 49 employees with a heavy concentration in research (43%) ## Competitive Advantages - **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition - **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable - **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding - **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic) ## Strategic Focus - Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors - Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology - Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth - Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development ## Why Work Here - **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed. - **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility. - **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.” - **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling. ## Sources 1. [Remix Therapeutics Home](https://www.remixtx.com/) 2. [Remix Therapeutics About Us](https://www.remixtx.com/about/) 3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/) 4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics) 5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)